Researchers compared clinicopathologic features, MammaPrint and BluePrint molecular subtype, and outcomes by race among patients with HR+, HER2− early-stage breast cancer.

Incidence and diagnosis of neuroendocrine tumors (NETs) have risen significantly over the last several decades. According to research published in JAMA Network Open in 2025, the incidence of NETs ...

(HealthDay News) — For patients with breast cancer, administration of pegfilgrastim 72 hours postchemotherapy reduces pegfilgrastim-induced bone pain (PIBP) compared with administration at 24 and 48 ...

In undertaking this survey, researchers aimed to assess the limitations of ctDNA testing in the clinic, as well as areas in which it is considered clinically meaningful.

FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to 3 prior systemic regimens.

The oral molecular glue degrader aims to overcome resistance to standard ALK tyrosine kinase inhibitor therapies.

Adstiladrin may now be thawed in a water bath following an FDA label update, facilitating more efficient treatment delivery for bladder cancer.

Now, without that federal financial help, some in this age group say they’re wrestling with whether to delay care until they ...

Investigators expanded on previous results from the DEAR study, comparing darolutamide versus enzalutamide and apalutamide ...

SCLC, researchers aimed to determine the consistency of benefit of adding PD-1/PD-L1 inhibitors to platinum-etoposide.

Psychosocial factors are not associated with an increased risk for most types of cancer, according to a study published online March 23 in Cancer. Lonneke A. van Tuijl, Ph.D., from the University ...

Thromboprophylaxis initiation is recommended for active hematological or gynecological cancers during pregnancy ...